Sort   by:  
 Page size 
UnknownEfficacy, Safety, and Patient-Reported Outcomes in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab for 5 Years in a Long-Term, Open-Label, Phase II Study.
Not available
S-EPMC6872506 | biostudies-literature
UnknownA head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial.
Not available
S-EPMC7317420 | biostudies-literature
Sort   by:  
 Page size